Fig. 1: The FSCN1 gene is downregulated by the androgen receptor in VCaP cells.

a RT-PCR evaluating expression levels of FSCN1 (right panel) from multiple cell lines (PC3c, PC3, PC3M-Luc, DU145, LNCaP, MDA-PCa-2b, VCaP) in which androgen receptor (AR) expression (left panel) was measured in parallel. Data were normalised to FSCN1 and AR levels in PC3c cells. b Western blot validating expression of AR and FSCN1 proteins in cell lines. GAPDH was used as a loading control. c RT-PCR showing FSCN1 expression in VCaP cells (right panel) according to AR activation in the presence of increasing doses (1–1000 nM) of dihydrotestosterone (DHT). Prostate-specific antigen (KLK3) expression (left panel) was a positive control of AR activation in the same experiment. Error bars indicate n = 3, mean +/− s.d. Statistical significance was determined by one-way ANOVA with a Dunnett multiple comparison test. d Western blot validating expression of FSCN1 in VCaP cells. β-actin was used as a loading control. e RT-PCR showing FSCN1 expression in VCaP cells (right panel) according to AR activation or repression respectively in the presence of increasing doses (1–1000 nM) of dihydrotestosterone (DHT) administered in the presence or the absence of 50 µM bicalutamide (BIC). Prostate-specific antigen (KLK3) expression (left panel) was a positive control of AR activation or repression in the same experiment. Error bars indicate mean +/− s.d. Statistical significance was determined by one-way ANOVA with a Dunnett multiple comparison test (n = 3). f Western blot validating expression of FSCN1 in VCaP cells. β-actin was used as a loading control. RT-PCR experiments were normalised to human L32 genes and run in triplicate.